VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With Renin-angiotensin System Inhibitors.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Paricalcitol (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms VITAL
- Sponsors Abbott Laboratories
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Actual patient nummber changed from 282 to 281 as reported by ClinicalTrials.gov.
- 17 Nov 2008 Planned end date changed from 1 Aug 2009 to 1 May 2009, according to ClinicalTrials.gov.